This TforG Healthcare Overview for Switzerland includes numerical and written analysis on the socioeconomic and macroeconomic context and outlook, the healthcare system, and the latest healthcare reforms. Moreover, an extensive chapter is dedicated to the markets for capital equipment, medical devices, disposables and pharmaceuticals.
The TforG Healthcare Overview is accessible through a user friendly Business Intelligence tool. Licenses are valid for 1 year.
- Switzerland ranks highly on life-quality indicators; e.g. for having one of the highest life expectancies and highest disposable incomes worldwide. It enjoys a wealthy modern market economy and one of the highest per capita GDPs in the world, reaching €60,498 per capita with a nominal GDP of €599 bn in 2015.
- Switzerland has adopted economic guidelines from the EU in order to improve its competitiveness and facilitate trade and business interactions. However, administrative barriers pose growth hindrances to small businesses currently and in the future.
- The inflation rate in 2015 is around -1.1% and it is expected to remain one of the lowest inflation rates in Europe in the next 3 years.
- Trade with its largest export partner the EU has decelerated in the last 5 years and the strong currency has been detrimental to competitiveness.
The Healthcare System:
- The Swiss healthcare system rates well in terms of patient satisfaction, short waiting lines for consultancy and elective surgery, service quality, excellent adoption of new technology and medication, and an overall healthy national status.
- Healthcare spending in Switzerland as a percentage of GDP in 2015 is around 11.6%, equivalent to €8,393 per capita. The overall expenditure and per capita rate is expected to decrease in the next 2 years by around €1,600 per capita and €12.6 bn in total.
- Cantons have the jurisdiction to structure healthcare as is deemed appropriate for their region, and this had led to a slightly different care organization from one canton to another.
- The health insurance companies in Switzerland are private and competing with one another, though there are certain basic guidelines and competitive restrictions. All insurance companies are obliged to offer the same fixed basic insurance package in terms of content.
- Reduced deductible categories for health insurance (2015)
- Inter-cantonal agreement for the financing of physician’s further education (2014)
- Union of Swiss Medical Board and SwissHTA (2014)
- Health2020 (2013)
- Dialogue National Health Policy (2013)
- Ensuring prevalence of future physicians (2013- ongoing)
- The medical device markets are expected to grow by around 2-3% come 2018. Growth is moderate due to imports declining, as the UK (one of Switzerland’s largest trading partners) executes the Brexit, and expenditure containment pressures are tightened.
- 6% of healthcare expenditure is spent on pharmaceuticals, equal to an estimated market value of €6 bn.
- The medical device market is valued at €3.2 bn, with an estimated growth rate of 2.5% from 2015 to 2018. Swiss medical device spending is amongst the highest worldwide.
- HTA is prevalent, yet not so powerful when making procurement choices; instead it is used most when creating reimbursement lists.
- Switzerland currently has low levels of centralized purchasing, but increasing cost pressures will lead to rapid increases of centralized procurement mechanisms.
- Switzerland enjoys a degree of medical tourism and a reputation for cutting edge medical procedures and treatments. Respectively and beyond these reasons, high-end sophisticated equipment is in demand.
Includes tables centralizing all relevant data on socio-demographics, macroeconomics and national Healthcare.
National Care Provision data:
Provides an overview of the Healthcare demographics: Nation Care provision data, Intensive Care units, Operating rooms, Emergency Rooms, Hospital services, Healthcare professionals.
© TforG Group – All Rights Reserved.